These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 31489705)

  • 41. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
    Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI.
    Harrington KD; Lim YY; Ellis KA; Copolov C; Darby D; Weinborn M; Ames D; Martins RN; Savage G; Szoeke C; Rowe C; Villemagne VL; Masters CL; Maruff P
    Int Psychogeriatr; 2013 Oct; 25(10):1667-77. PubMed ID: 23866942
    [TBL] [Abstract][Full Text] [Related]  

  • 45. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
    Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
    JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
    Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.
    Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P
    J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. White matter microstructural damage and depressive symptoms in patients with mild cognitive impairment and cerebral small vessel disease: the VMCI-Tuscany Study.
    Pasi M; Poggesi A; Salvadori E; Diciotti S; Ciolli L; Del Bene A; Marini S; Nannucci S; Pescini F; Valenti R; Ginestroni A; Toschi N; Mascalchi M; Inzitari D; Pantoni L
    Int J Geriatr Psychiatry; 2016 Jun; 31(6):611-8. PubMed ID: 26489377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
    Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
    JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.
    Kemppainen N; Joutsa J; Johansson J; Scheinin NM; Någren K; Rokka J; Parkkola R; Rinne JO
    J Alzheimers Dis; 2015; 48(1):123-33. PubMed ID: 26401934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimer's disease in mild cognitive impairment patients.
    Ciarmiello A; Tartaglione A; Giovannini E; Riondato M; Giovacchini G; Ferrando O; De Biasi M; Passera C; Carabelli E; Mannironi A; Foppiano F; Alfano B; Mansi L
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):288-296. PubMed ID: 30244387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation.
    Arenaza-Urquijo EM; Bejanin A; Gonneaud J; Wirth M; La Joie R; Mutlu J; Gaubert M; Landeau B; de la Sayette V; Eustache F; Chételat G
    Neurobiol Aging; 2017 Nov; 59():72-79. PubMed ID: 28764930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
    Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
    Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Applying the ATN scheme in a memory clinic population: The ABIDE project.
    Altomare D; de Wilde A; Ossenkoppele R; Pelkmans W; Bouwman F; Groot C; van Maurik I; Zwan M; Yaqub M; Barkhof F; van Berckel BN; Teunissen CE; Frisoni GB; Scheltens P; van der Flier WM
    Neurology; 2019 Oct; 93(17):e1635-e1646. PubMed ID: 31597710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between
    Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
    Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors related to prevalence, persistence, and incidence of depressive symptoms in mild cognitive impairment: vascular depression construct.
    Kim S; Woo SY; Kang HS; Lim SW; Choi SH; Myung W; Jeong JH; Lee Y; Hong CH; Kim JH; Na H; Carroll BJ; Kim DK
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):818-26. PubMed ID: 26679895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.